4 minute read
Aug. 26, 2022

"Compound 33" is a cGMP-Dependent Protein Kinase G1α (PKG1α) Activator

compound 33

intravenous PKG1α activator satisfactory in vivo rat PK profile from 2.9 M compounds HTS, SBDD and opt J. Med. Chem., July 25, 2022 Merck & Co., Inc., South San Francisco, CA

Drug Hunter Team

Context. “ Compound 33 ” (Merck) is a cGMP-dependent protein kinase G1α (PKG1α) activator cGMP modulation is considered one of the most promising approaches for cardiovascular drug discovery with >30 agents either approved for use or in various stages of clinical development. Although PKGs are the main effector of cGMP, cardiovascular drug [...]



Other molecules you may be interested in